-
Otonomy Rips 90% After Meniere's Disease Drug Achieves Primary Endpoint
Thursday, November 9, 2017 - 11:51am | 460Read More...Otonomy Inc (NASDAQ: OTIC), a biopharmaceutical company that focuses on therapies related to diseases and disorders of the ear, reported its third-quarter results and announced an encouraging update to a phase 2 trial. What You Need To Know Otonomy lost 69 cents in its third quarter on revenue of...
-
Ironwood's Pipeline Needs Work, Analyst Downgrades
Friday, July 21, 2017 - 10:47am | 312Read More...Analysts at JPMorgan no longer hold a bullish view on Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) after the company released top-line results from a phase 2b trial called IW-3718. The firm's Anupam Rama downgraded Ironwood's stock from Overweight to Neutral with a price target lowered...
-
Getting Into The Drug Business: From NDAs To PDUFA Dates
Tuesday, September 27, 2016 - 2:20pm | 665Read More...The strongest catalysts for a pharma stock are the various milestones on the road to FDA approval for new drugs. For new investors, they’ll often see a stock rise astronomically, but, when they go to make sense of the reasons for the jump, they’re greeted with unfamiliar acronyms. Let...
-
Synthetic Biologics Crashes Following Disappointing Phase 2 Results
Tuesday, February 2, 2016 - 2:36pm | 215Read More...Shares of Synthetic Biologics Inc (NYSE: SYN), a clinical-stage biotechnology company, lost more than 16 percent and hit a new 52-week low of $1.17 on Tuesday after the company released results of an independent third party evaluation of its Phase 2 clinical trial. Synthetic Biologics's...
-
Novo Nordisk Announces Positive Phase 2 Trial Results, Shares Spike Higher
Friday, February 20, 2015 - 12:14pm | 107Read More...Shares of Novo Nordisk A/S (NYSE: NVO) were trading higher by more than 4 percent Friday morning after the company announced positive results from a phase 2 FDA trial. Novo Nordisk announced that it "has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting...
